Loading…
The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial
Background In this double‐blinded, randomized trial, we hypothesized that propofol is as effective as sumatriptan in treating acute migraine headaches, with better control of nausea and vomiting, and fewer side effects. Methods Ninety cases of acute migraine attack admitted to the emergency departme...
Saved in:
Published in: | Pain practice 2015-11, Vol.15 (8), p.701-705 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4700-4f4ad82441112a8ece5fcafeb3004939b841d9438c69ff7dd4b89a2b892df9423 |
---|---|
cites | cdi_FETCH-LOGICAL-c4700-4f4ad82441112a8ece5fcafeb3004939b841d9438c69ff7dd4b89a2b892df9423 |
container_end_page | 705 |
container_issue | 8 |
container_start_page | 701 |
container_title | Pain practice |
container_volume | 15 |
creator | Moshtaghion, Hossein Heiranizadeh, Najmeh Rahimdel, Abolghasem Esmaeili, Alireza Hashemian, Hamidreza Hekmatimoghaddam, Seyedhossein |
description | Background
In this double‐blinded, randomized trial, we hypothesized that propofol is as effective as sumatriptan in treating acute migraine headaches, with better control of nausea and vomiting, and fewer side effects.
Methods
Ninety cases of acute migraine attack admitted to the emergency department were randomly allocated into two treatment groups: (1) 6 mg of sumatriptan subcutaneously or (2) propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4. Headache severity was assessed using an 11‐point visual analog scale before treatment and 30 minutes, 1 hour, and 2 hours after treatment. Accompanying symptoms, improvement in headache, and the need for anti‐emetic therapy were also assessed.
Results
A total of 91 patients were enrolled in this study. One patient in the sumatriptan group was excluded due to severe chest tightness, and 90 patients were included in the final analysis. Pain intensity was significantly lower in the propofol group 30 minutes after treatment (P = 0.001); however, after 1 and 2 hours, there were no significant differences between the groups. The need for anti‐emetic therapy and the recurrence of symptoms were significantly lower in the propofol group (P = 0.045 and P = 0.001, respectively).
Conclusion
Propofol is equally suitable as sumatriptan for the acute treatment of migraine headaches in an emergency department setting. Moreover, the use of propofol avoids some of the adverse side effects of sumatriptan while providing better control of nausea and vomiting. |
doi_str_mv | 10.1111/papr.12230 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1815693156</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1730682725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4700-4f4ad82441112a8ece5fcafeb3004939b841d9438c69ff7dd4b89a2b892df9423</originalsourceid><addsrcrecordid>eNqFkc9u1DAQxiMEoqVw4QGQjwgpi_9l43BbtqVFKrAqizhajj1uDU4c7ATYd-Fh8W7aHsGHsUf-fd-MPUXxnOAFyev1oIa4IJQy_KA4JhVjJa0wfng447LGojoqnqT0DWNSN4w9Lo7yPceMkuPiz_YG0Jm1Tiu9Q8GiTQxDsMGjn2mBPk-tnkbVQ5hSTjo1RjfkHNkQ0TaCGjvox71slTlAH9x1VK4HdAHKKH0DCbkejfsSHcRr6HONUxhUPOjeoBU6DVProXzrXW_AoHXecys-mzvlnxaPrPIJnt3uJ8WXd2fb9UV5-en8_Xp1WWpeY1xyy5URlPP8GVQJ0FBZrSy0DGPesKYVnJiGM6GXjbW1MbwVjaI5UGMbTtlJ8XL2HWL4MUEaZeeSBu_nl0siSLVsWA7_R2uGl4LWtMroqxnVMaQUwcohuk7FnSRY7gcn94OTh8Fl-MWt79R2YO7Ru0llgMzAL-dh9w8ruVltru5My1nj0gi_7zUqfpfLmtWV_PrxXIpN7pduubxifwFlY7Lu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1730682725</pqid></control><display><type>article</type><title>The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Moshtaghion, Hossein ; Heiranizadeh, Najmeh ; Rahimdel, Abolghasem ; Esmaeili, Alireza ; Hashemian, Hamidreza ; Hekmatimoghaddam, Seyedhossein</creator><creatorcontrib>Moshtaghion, Hossein ; Heiranizadeh, Najmeh ; Rahimdel, Abolghasem ; Esmaeili, Alireza ; Hashemian, Hamidreza ; Hekmatimoghaddam, Seyedhossein</creatorcontrib><description>Background
In this double‐blinded, randomized trial, we hypothesized that propofol is as effective as sumatriptan in treating acute migraine headaches, with better control of nausea and vomiting, and fewer side effects.
Methods
Ninety cases of acute migraine attack admitted to the emergency department were randomly allocated into two treatment groups: (1) 6 mg of sumatriptan subcutaneously or (2) propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4. Headache severity was assessed using an 11‐point visual analog scale before treatment and 30 minutes, 1 hour, and 2 hours after treatment. Accompanying symptoms, improvement in headache, and the need for anti‐emetic therapy were also assessed.
Results
A total of 91 patients were enrolled in this study. One patient in the sumatriptan group was excluded due to severe chest tightness, and 90 patients were included in the final analysis. Pain intensity was significantly lower in the propofol group 30 minutes after treatment (P = 0.001); however, after 1 and 2 hours, there were no significant differences between the groups. The need for anti‐emetic therapy and the recurrence of symptoms were significantly lower in the propofol group (P = 0.045 and P = 0.001, respectively).
Conclusion
Propofol is equally suitable as sumatriptan for the acute treatment of migraine headaches in an emergency department setting. Moreover, the use of propofol avoids some of the adverse side effects of sumatriptan while providing better control of nausea and vomiting.</description><identifier>ISSN: 1530-7085</identifier><identifier>EISSN: 1533-2500</identifier><identifier>DOI: 10.1111/papr.12230</identifier><identifier>PMID: 25040321</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Anesthetics, Intravenous - administration & dosage ; Double-Blind Method ; emergency department ; Emergency Service, Hospital ; Female ; headache ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; Male ; Middle Aged ; migraine ; Migraine Disorders - drug therapy ; propofol ; Propofol - administration & dosage ; Propofol - adverse effects ; Serotonin 5-HT1 Receptor Agonists - administration & dosage ; sumatriptan ; Sumatriptan - administration & dosage ; Sumatriptan - adverse effects ; treatment</subject><ispartof>Pain practice, 2015-11, Vol.15 (8), p.701-705</ispartof><rights>2014 World Institute of Pain</rights><rights>2014 World Institute of Pain.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4700-4f4ad82441112a8ece5fcafeb3004939b841d9438c69ff7dd4b89a2b892df9423</citedby><cites>FETCH-LOGICAL-c4700-4f4ad82441112a8ece5fcafeb3004939b841d9438c69ff7dd4b89a2b892df9423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25040321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moshtaghion, Hossein</creatorcontrib><creatorcontrib>Heiranizadeh, Najmeh</creatorcontrib><creatorcontrib>Rahimdel, Abolghasem</creatorcontrib><creatorcontrib>Esmaeili, Alireza</creatorcontrib><creatorcontrib>Hashemian, Hamidreza</creatorcontrib><creatorcontrib>Hekmatimoghaddam, Seyedhossein</creatorcontrib><title>The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial</title><title>Pain practice</title><addtitle>Pain Pract</addtitle><description>Background
In this double‐blinded, randomized trial, we hypothesized that propofol is as effective as sumatriptan in treating acute migraine headaches, with better control of nausea and vomiting, and fewer side effects.
Methods
Ninety cases of acute migraine attack admitted to the emergency department were randomly allocated into two treatment groups: (1) 6 mg of sumatriptan subcutaneously or (2) propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4. Headache severity was assessed using an 11‐point visual analog scale before treatment and 30 minutes, 1 hour, and 2 hours after treatment. Accompanying symptoms, improvement in headache, and the need for anti‐emetic therapy were also assessed.
Results
A total of 91 patients were enrolled in this study. One patient in the sumatriptan group was excluded due to severe chest tightness, and 90 patients were included in the final analysis. Pain intensity was significantly lower in the propofol group 30 minutes after treatment (P = 0.001); however, after 1 and 2 hours, there were no significant differences between the groups. The need for anti‐emetic therapy and the recurrence of symptoms were significantly lower in the propofol group (P = 0.045 and P = 0.001, respectively).
Conclusion
Propofol is equally suitable as sumatriptan for the acute treatment of migraine headaches in an emergency department setting. Moreover, the use of propofol avoids some of the adverse side effects of sumatriptan while providing better control of nausea and vomiting.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthetics, Intravenous - administration & dosage</subject><subject>Double-Blind Method</subject><subject>emergency department</subject><subject>Emergency Service, Hospital</subject><subject>Female</subject><subject>headache</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Injections, Subcutaneous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>propofol</subject><subject>Propofol - administration & dosage</subject><subject>Propofol - adverse effects</subject><subject>Serotonin 5-HT1 Receptor Agonists - administration & dosage</subject><subject>sumatriptan</subject><subject>Sumatriptan - administration & dosage</subject><subject>Sumatriptan - adverse effects</subject><subject>treatment</subject><issn>1530-7085</issn><issn>1533-2500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFkc9u1DAQxiMEoqVw4QGQjwgpi_9l43BbtqVFKrAqizhajj1uDU4c7ATYd-Fh8W7aHsGHsUf-fd-MPUXxnOAFyev1oIa4IJQy_KA4JhVjJa0wfng447LGojoqnqT0DWNSN4w9Lo7yPceMkuPiz_YG0Jm1Tiu9Q8GiTQxDsMGjn2mBPk-tnkbVQ5hSTjo1RjfkHNkQ0TaCGjvox71slTlAH9x1VK4HdAHKKH0DCbkejfsSHcRr6HONUxhUPOjeoBU6DVProXzrXW_AoHXecys-mzvlnxaPrPIJnt3uJ8WXd2fb9UV5-en8_Xp1WWpeY1xyy5URlPP8GVQJ0FBZrSy0DGPesKYVnJiGM6GXjbW1MbwVjaI5UGMbTtlJ8XL2HWL4MUEaZeeSBu_nl0siSLVsWA7_R2uGl4LWtMroqxnVMaQUwcohuk7FnSRY7gcn94OTh8Fl-MWt79R2YO7Ru0llgMzAL-dh9w8ruVltru5My1nj0gi_7zUqfpfLmtWV_PrxXIpN7pduubxifwFlY7Lu</recordid><startdate>201511</startdate><enddate>201511</enddate><creator>Moshtaghion, Hossein</creator><creator>Heiranizadeh, Najmeh</creator><creator>Rahimdel, Abolghasem</creator><creator>Esmaeili, Alireza</creator><creator>Hashemian, Hamidreza</creator><creator>Hekmatimoghaddam, Seyedhossein</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>201511</creationdate><title>The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial</title><author>Moshtaghion, Hossein ; Heiranizadeh, Najmeh ; Rahimdel, Abolghasem ; Esmaeili, Alireza ; Hashemian, Hamidreza ; Hekmatimoghaddam, Seyedhossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4700-4f4ad82441112a8ece5fcafeb3004939b841d9438c69ff7dd4b89a2b892df9423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthetics, Intravenous - administration & dosage</topic><topic>Double-Blind Method</topic><topic>emergency department</topic><topic>Emergency Service, Hospital</topic><topic>Female</topic><topic>headache</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Injections, Subcutaneous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>propofol</topic><topic>Propofol - administration & dosage</topic><topic>Propofol - adverse effects</topic><topic>Serotonin 5-HT1 Receptor Agonists - administration & dosage</topic><topic>sumatriptan</topic><topic>Sumatriptan - administration & dosage</topic><topic>Sumatriptan - adverse effects</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moshtaghion, Hossein</creatorcontrib><creatorcontrib>Heiranizadeh, Najmeh</creatorcontrib><creatorcontrib>Rahimdel, Abolghasem</creatorcontrib><creatorcontrib>Esmaeili, Alireza</creatorcontrib><creatorcontrib>Hashemian, Hamidreza</creatorcontrib><creatorcontrib>Hekmatimoghaddam, Seyedhossein</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Pain practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moshtaghion, Hossein</au><au>Heiranizadeh, Najmeh</au><au>Rahimdel, Abolghasem</au><au>Esmaeili, Alireza</au><au>Hashemian, Hamidreza</au><au>Hekmatimoghaddam, Seyedhossein</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial</atitle><jtitle>Pain practice</jtitle><addtitle>Pain Pract</addtitle><date>2015-11</date><risdate>2015</risdate><volume>15</volume><issue>8</issue><spage>701</spage><epage>705</epage><pages>701-705</pages><issn>1530-7085</issn><eissn>1533-2500</eissn><abstract>Background
In this double‐blinded, randomized trial, we hypothesized that propofol is as effective as sumatriptan in treating acute migraine headaches, with better control of nausea and vomiting, and fewer side effects.
Methods
Ninety cases of acute migraine attack admitted to the emergency department were randomly allocated into two treatment groups: (1) 6 mg of sumatriptan subcutaneously or (2) propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4. Headache severity was assessed using an 11‐point visual analog scale before treatment and 30 minutes, 1 hour, and 2 hours after treatment. Accompanying symptoms, improvement in headache, and the need for anti‐emetic therapy were also assessed.
Results
A total of 91 patients were enrolled in this study. One patient in the sumatriptan group was excluded due to severe chest tightness, and 90 patients were included in the final analysis. Pain intensity was significantly lower in the propofol group 30 minutes after treatment (P = 0.001); however, after 1 and 2 hours, there were no significant differences between the groups. The need for anti‐emetic therapy and the recurrence of symptoms were significantly lower in the propofol group (P = 0.045 and P = 0.001, respectively).
Conclusion
Propofol is equally suitable as sumatriptan for the acute treatment of migraine headaches in an emergency department setting. Moreover, the use of propofol avoids some of the adverse side effects of sumatriptan while providing better control of nausea and vomiting.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25040321</pmid><doi>10.1111/papr.12230</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1530-7085 |
ispartof | Pain practice, 2015-11, Vol.15 (8), p.701-705 |
issn | 1530-7085 1533-2500 |
language | eng |
recordid | cdi_proquest_miscellaneous_1815693156 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adult Aged Anesthetics, Intravenous - administration & dosage Double-Blind Method emergency department Emergency Service, Hospital Female headache Humans Injections, Intravenous Injections, Subcutaneous Male Middle Aged migraine Migraine Disorders - drug therapy propofol Propofol - administration & dosage Propofol - adverse effects Serotonin 5-HT1 Receptor Agonists - administration & dosage sumatriptan Sumatriptan - administration & dosage Sumatriptan - adverse effects treatment |
title | The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A45%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Efficacy%20of%20Propofol%20vs.%20Subcutaneous%20Sumatriptan%20for%20Treatment%20of%20Acute%20Migraine%20Headaches%20in%20the%20Emergency%20Department:%20A%20Double-Blinded%20Clinical%20Trial&rft.jtitle=Pain%20practice&rft.au=Moshtaghion,%20Hossein&rft.date=2015-11&rft.volume=15&rft.issue=8&rft.spage=701&rft.epage=705&rft.pages=701-705&rft.issn=1530-7085&rft.eissn=1533-2500&rft_id=info:doi/10.1111/papr.12230&rft_dat=%3Cproquest_cross%3E1730682725%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4700-4f4ad82441112a8ece5fcafeb3004939b841d9438c69ff7dd4b89a2b892df9423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1730682725&rft_id=info:pmid/25040321&rfr_iscdi=true |